• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of a new therapeutic modality using YAP1/TAZ inhibitors against malignant mesothelioma

Research Project

Project/Area Number 19H03527
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 50020:Tumor diagnostics and therapeutics-related
Research InstitutionAichi Cancer Center Research Institute

Principal Investigator

Sekido Yoshitaka  愛知県がんセンター(研究所), 分子腫瘍学分野, 副所長兼分野長 (00311712)

Co-Investigator(Kenkyū-buntansha) 佐藤 龍洋  愛知県がんセンター(研究所), 分子腫瘍学分野, 主任研究員 (70547893)
向井 智美  愛知県がんセンター(研究所), 分子腫瘍学分野, 研究員 (10706146)
Project Period (FY) 2019-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2021: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2020: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2019: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Keywords悪性中皮腫 / 細胞株 / 分子標的薬 / シグナル伝達系 / 遺伝子変異 / 細胞増殖 / 分子標的治療 / Hippoシグナル伝達系
Outline of Research at the Start

アスベスト曝露により発生する悪性中皮腫はNF2遺伝子とヒッポ細胞内シグナル伝達系がしばしば不活化している。ヒッポシグナル伝達系の不活化はYAP1/TAZという、がん促進性の蛋白を活性化させる。国内外のグループで開発が進んでいるYAP1/TAZ阻害剤について、独自に樹立した悪性中皮腫細胞株パネルを利用して効果を明らかにすると共に効果予測バイオマーカーの同定を試みる。さらに、YAP1/TAZ阻害剤に対する耐性機構の解明や、併用療法として期待される薬剤の同定を行う。これらの検討から、悪性中皮腫患者に対するYAP1/TAZ阻害剤を用いた臨床試験へ展開するための強力なエビデンスを得ることを目指す。

Outline of Final Research Achievements

Malignant mesothelioma promotes cell proliferation and progression of tumor cells through the constitutive activation of YAP1/TAZ coactivators involved in gene transcription. Through collaborative research, we have developed a novel YAP1/TAZ inhibitor. The sensitivities of the newly developed inhibitor K-975 as well as other YAP1/TAZ inhibitors were examined and characterized using an established panel of Japanese malignant mesothelioma cell lines by ourselves. Furthermore, we succeeded in establishing acquired resistant strains using the cell lines that initially showed high sensitivity, and clarified the mechanism of resistance. The results of this study may lead to new therapeutic strategies for malignant mesothelioma.

Academic Significance and Societal Importance of the Research Achievements

悪性中皮腫に対する化学療法薬は極めて限られている。免疫チェックポイント阻害剤も2剤が最近保険収載されたが、実臨床での奏効率は期待されたほど高くない。本研究によりYAP1/TAZ阻害剤がNF2-Hippoシグナル伝達系が高頻度に破綻している悪性中皮腫細胞に対して強い抗腫瘍効果を示すことが明らかとなった。さらに、感受性や獲得耐性に関する機構についても明らかになった。今後、YAP1/TAZ阻害剤を臨床試験に展開するために非常に有用な知見が得られたものと考えられる。

Report

(4 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Annual Research Report
  • 2019 Annual Research Report
  • Research Products

    (30 results)

All 2021 2020 2019 Other

All Journal Article (9 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 9 results,  Open Access: 7 results) Presentation (19 results) (of which Int'l Joint Research: 2 results,  Invited: 8 results) Book (1 results) Remarks (1 results)

  • [Journal Article] Lysosomal nitric oxide determines transition from autophagy to ferroptosis after exposure to plasma-activated Ringer's lactate2021

    • Author(s)
      Jiang Li、Zheng Hao、Lyu Qinying、Hayashi Shotaro、Sato Kotaro、Sekido Yoshitaka、Nakamura Kae、Tanaka Hiromasa、Ishikawa Kenji、Kajiyama Hiroaki、Mizuno Masaaki、Hori Masaru、Toyokuni Shinya
    • Journal Title

      Redox Biology

      Volume: 43 Pages: 101989-101989

    • DOI

      10.1016/j.redox.2021.101989

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models2021

    • Author(s)
      Goto Shunsuke、Sakoda Yukimi、Adachi Keishi、Sekido Yoshitaka、Yano Seiji、Eto Masatoshi、Tamada Koji
    • Journal Title

      Cancer Immunology, Immunotherapy

      Volume: 70 Issue: 9 Pages: 2503-2515

    • DOI

      10.1007/s00262-021-02853-3

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Oxytocin receptor is a promising therapeutic target of malignant mesothelioma2021

    • Author(s)
      Oxytocin receptor is a promising therapeutic target of malignant mesothelioma. Kodama Y, Tanaka I, Sato T, Hori K, Gen S, Morise M, Matsubara D, Sato M, Sekido Y, Hashimoto N.
    • Journal Title

      Cancer science

      Volume: 112 Issue: 9 Pages: 3520-3532

    • DOI

      10.1111/cas.15025

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively2021

    • Author(s)
      Sato Tatsuhiro、Nakanishi Hayao、Akao Ken、Okuda Maho、Mukai Satomi、Kiyono Tohru、Sekido Yoshitaka
    • Journal Title

      Cancer Cell International

      Volume: 21 Issue: 1 Pages: 546-546

    • DOI

      10.1186/s12935-021-02248-5

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD12021

    • Author(s)
      Wirawan Aditya、Tajima Ken、Takahashi Fumiyuki、Mitsuishi Yoichiro、Winardi Wira、Hidayat Moulid、Hayakawa Daisuke、Matsumoto Naohisa、Izumi Kenta、Asao Tetsuhiko、Ko Ryo、Shimada Naoko、Takamochi Kazuya、Suzuki Kenji、Abe Masaaki、Hino Okio、Sekido Yoshitaka、Takahashi Kazuhisa
    • Journal Title

      Molecular Cancer Research

      Volume: 20 Issue: 1 Pages: 127-138

    • DOI

      10.1158/1541-7786.mcr-21-0230

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Silencing of SmgGDS, a Novel mTORC1 Inducer That Binds to RHEBs, Inhibits Malignant Mesothelioma Cell Proliferation2021

    • Author(s)
      Sato Tatsuhiro、Mukai Satomi、Ikeda Haruna、Mishiro-Sato Emi、Akao Ken、Kobayashi Toshiyuki、Hino Okio、Shimono Wataru、Shibagaki Yoshio、Hattori Seisuke、Sekido Yoshitaka
    • Journal Title

      Molecular Cancer Research

      Volume: - Issue: 5 Pages: 921-931

    • DOI

      10.1158/1541-7786.mcr-20-0637

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma2020

    • Author(s)
      Kaneda A, Seike T, Danjo T, Nakajima T, Otsubo N, Yamaguchi D, Tsuji Y, Hamaguchi K, Yasunaga M, Nishiya Y, Suzuki M, Saito JI, Yatsunami R, Nakamura S, Sekido Y, Mori K.
    • Journal Title

      Am J Cancer Res

      Volume: 10 Pages: 4399-4415

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Frequent homozygous deletion of Cdkn2a/2b in tremolite‐induced malignant mesothelioma in rats2020

    • Author(s)
      Okazaki Yasumasa、Misawa Nobuaki、Akatsuka Shinya、Kohyama Norihiko、Sekido Yoshitaka、Takahashi Takashi、Toyokuni Shinya
    • Journal Title

      Cancer Science

      Volume: N/A Issue: 4 Pages: 1180-1192

    • DOI

      10.1111/cas.14358

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Carbonic anhydrase 9 confers resistance to ferroptosis/apoptosis in malignant mesothelioma under hypoxia2019

    • Author(s)
      Li Zan、Jiang Li、Chew Shan Hwu、Hirayama Tasuku、Sekido Yoshitaka、Toyokuni Shinya
    • Journal Title

      Redox Biology

      Volume: 26 Pages: 101297-101297

    • DOI

      10.1016/j.redox.2019.101297

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] NF22021

    • Author(s)
      関戸好孝
    • Organizer
      iMig2021
    • Related Report
      2021 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] LATS2変異悪性中皮腫に対する新規合成致死遺伝子を標的とした抗腫瘍活性の包括的評価2021

    • Author(s)
      鈴木浩也、向井智美、三井田孝、関戸好孝、村上(渡並)優子
    • Organizer
      第25回日本がん分子標的治療学会学術集会
    • Related Report
      2021 Annual Research Report
  • [Presentation] BAP1変異悪性中皮腫細胞株におけるCHK2の役割2021

    • Author(s)
      丹下将希、鈴木浩也、三井田孝、関戸好孝、村上(渡並)優子
    • Organizer
      第25回日本がん分子標的治療学会学術集会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 悪性中皮腫細胞に対する新規TEAD阻害剤の効果の検討2021

    • Author(s)
      赤尾謙、佐藤龍洋、向井智美、平野雅規、関戸好孝
    • Organizer
      第2回日本石綿・中皮腫学会学術集会
    • Related Report
      2021 Annual Research Report
  • [Presentation] ロングリードシーケンシングによるヒト中皮腫ゲノム変異の特徴の研究2021

    • Author(s)
      陳イクアン、永江玄太、上田宏生、辰野健二、森下真一、関戸好孝、油谷浩幸
    • Organizer
      第80回 日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 悪性中皮腫において BAP1 変異と合成致死表現型を示す遺伝子の機能解析2021

    • Author(s)
      小林輝星、鈴木浩也、三井田 孝、関戸好孝、村上(渡並) 優子
    • Organizer
      第80回 日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 悪性中皮腫のゲノム異常と細胞特性2021

    • Author(s)
      関戸好孝
    • Organizer
      第48回産業中毒・生物学的モニタリング研究会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] 隣接細胞への浸潤機構「エントーシス」に関わる新たな分子機序とその役割2021

    • Author(s)
      佐藤龍洋、関戸好孝
    • Organizer
      第44回日本分子生物学会年会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 悪性中皮腫におけるO-GlcNAc修飾異常を介した腫瘍進展メカニズムの解明2021

    • Author(s)
      向井智美、佐藤龍洋、三城恵美、青木正博、藪田紀一、関戸好孝
    • Organizer
      第44回日本分子生物学会年会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 「肺癌・中皮腫の病理とゲノム異常」中皮腫におけるゲノム異常2020

    • Author(s)
      関戸好孝
    • Organizer
      第109回日本病理学会総会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] SmgGDSの発現抑制はmTORC1を抑制し悪性中皮腫の増殖を阻止する(抑制する)2020

    • Author(s)
      関戸好孝、佐藤龍洋
    • Organizer
      第24回日本がん分子標的治療学会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 悪性胸膜中皮腫における基礎研究Up-to-date2020

    • Author(s)
      関戸好孝
    • Organizer
      第61回日本肺癌学会学術集会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] 悪性中皮腫細胞株の樹立:遺伝子異常の本態解析から臨床応用を目指して2019

    • Author(s)
      関戸好孝
    • Organizer
      日本組織培養学会 第92回大会
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] 悪性中皮腫におけるHippo経路のターゲッティング2019

    • Author(s)
      関戸好孝
    • Organizer
      2019 World Conference on Lung Cancer
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] 中皮腫におけるmTORシグナル伝達経路の活性化と新規治療標的因子の探索2019

    • Author(s)
      佐藤龍洋、関戸好孝
    • Organizer
      第1回日本石綿・中皮腫学会学術集会
    • Related Report
      2019 Annual Research Report
  • [Presentation] O-GlcNAc修飾は悪性中皮腫の腫瘍進展を促進する2019

    • Author(s)
      向井智美、佐藤龍洋、三城(佐藤)恵美、青木正博、藪田紀一、関戸好孝
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 悪性中皮腫の遺伝子変異2019

    • Author(s)
      関戸好孝
    • Organizer
      藤田学園医学会第51回総会
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] SmgGDSによるRheb-mTORC1シグナル伝達制御と悪性中皮種がん化への関与2019

    • Author(s)
      佐藤龍洋、向井智美、関戸好孝
    • Organizer
      第42回日本分子生物学会年会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 悪性中皮腫における基礎研究の進歩2019

    • Author(s)
      関戸好孝
    • Organizer
      第60回日本肺癌学会学術集会
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Book] Malignant mesothelioma Advances in Pathogenesis, Diagnosis, and Treatments2021

    • Author(s)
      Sekido Y
    • Total Pages
      352
    • Publisher
      Springer
    • Related Report
      2021 Annual Research Report
  • [Remarks] 分子腫瘍学分野 研究紹介(専門家向け) 悪性中皮腫におけるHippoシグナル伝達系異常の解明

    • URL

      https://www.pref.aichi.jp/cancer-center/ri/01bumon/03bunshi_shuyo/02kenkyu_senmon.html

    • Related Report
      2019 Annual Research Report

URL: 

Published: 2019-04-18   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi